Comparative Pharmacology
Head-to-head clinical analysis: DIENESTROL versus DROSPIRENONE AND ESTRADIOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIENESTROL versus DROSPIRENONE AND ESTRADIOL.
DIENESTROL vs DROSPIRENONE AND ESTRADIOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Synthetic nonsteroidal estrogen that binds to estrogen receptors, activating transcription of estrogen-responsive genes, leading to effects similar to endogenous estrogens.
Drospirenone is a progestin with antimineralocorticoid and antiandrogenic activity; estradiol is an estrogen. Drospirenone acts as a progesterone receptor agonist, inhibits ovulation, and increases cervical mucus viscosity. Estradiol replaces endogenous estrogen, suppresses gonadotropin secretion.
0.1 to 0.5 mg orally once daily for estrogen replacement therapy; 0.5 to 1.0 mg orally once daily for prostatic carcinoma.
One tablet (drospirenone 3 mg / estradiol 0.5 mg) orally once daily for hormone therapy.
None Documented
None Documented
Clinical Note
moderateDienestrol + Etoricoxib
"Dienestrol may increase the thrombogenic activities of Etoricoxib."
Clinical Note
moderateDienestrol + Parecoxib
"Dienestrol may increase the thrombogenic activities of Parecoxib."
Clinical Note
moderateDienestrol + Voriconazole
"The metabolism of Voriconazole can be decreased when combined with Dienestrol."
Clinical Note
moderateDienestrol + Lumiracoxib
"Dienestrol may increase the thrombogenic activities of Lumiracoxib."
Terminal elimination half-life is approximately 24-48 hours, longer with hepatic impairment.
Drospirenone: ~30-40 hours (allows once-daily dosing); estradiol: ~12-15 hours (after oral administration).
Primarily renal (40-60% as glucuronide conjugates) and biliary/fecal (30-50% with enterohepatic recycling).
Drospirenone: ~40-50% renal, ~50-60% fecal; estradiol: ~60-80% renal (as metabolites), ~20-40% fecal.
Category C
Category D/X
Estrogen
Estrogen